Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women
Status:
Completed
Trial end date:
2019-01-30
Target enrollment:
Participant gender:
Summary
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group
study designed to evaluate the efficacy, safety, and tolerability of solabegron immediate
release low dose or high dose tablets, compared to matched placebo, administered twice daily
for 12 weeks to adult female subjects with overactive bladder symptoms (frequency, urgency,
and predominantly urgency incontinence) for at least 6 months.